Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.


 (lī′gənd, lĭg′ənd)
An ion, molecule, or molecular group that binds to another chemical entity to form a larger complex.

[From Latin ligandus, gerundive of ligāre, to bind; see ligate.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(ˈlɪɡənd; ˈlaɪ-)
(Chemistry) chem an atom, molecule, radical, or ion forming a complex with a central atom
[C20: from Latin ligandum, gerund of ligāre to bind]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014


(ˈlaɪ gənd, ˈlɪg ənd)

1. a molecule, as an antibody, hormone, or drug, that binds to a receptor.
2. a molecule, ion, or atom that is bonded to the central metal atom of a coordination compound.
[1945–50; < Latin ligandus, ger. of ligāre to bind, tie]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.ligand - a substance (an atom or molecule or radical or ion) that forms a complex around a central atom
substance - a particular kind or species of matter with uniform properties; "shigella is one of the most toxic substances known to man"
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
The ligand was synthesized from the Betulinic acid by the reported method as shown in the scheme-2[14].
Release date- 29082019 - SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.C.
M2 EQUITYBITES-August 5, 2019-Lemelson Capital increases short position in Ligand Pharmaceuticals (NASDAQ: LGND)
Global Banking News-August 5, 2019-Lemelson Capital increases short position in Ligand Pharmaceuticals (NASDAQ: LGND)
BANKING AND CREDIT NEWS-August 5, 2019-Lemelson Capital increases short position in Ligand Pharmaceuticals (NASDAQ: LGND)
Ligand Pharmaceuticals Incorporated has signed an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash.
On Tuesday, Ligand short seller Lemelson Capital Management said the firm has been adding to its short position against Ligand and is calling for an investigation into alleged crimes committed by the company.
Ligand Pharmaceuticals said this morning in its earnings release, "Metavant has been working with FDA to determine a path forward for the glucagon receptor antagonist or GRA program now known as RVT-1502 in diabetes.
26 July 2019- California, US-based drugmaker Ligand Pharmaceuticals Inc.
United States-based Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a contract to acquire United States-based Ab Initio Biotherapeutics, it was reported yesterday.
The proposed geometries of the complexes were established on the basis of metal ligand ratio through ICP.
Emmanuel Lemelson and his private investment firm Lemelson Capital Management, LLC (collectively, 'Lemelson') publicized false information about biopharmaceutical company Ligand Pharmaceuticals ('Ligand') after Lemelson took a short position in Ligand in May 2014 on behalf of The Amvona Fund a hedge fund Lemelson advises and partly owns.

Full browser ?